CKDXF (Ceryvyn Therapeutics) Effective Interest Rate on Debt %: 30.88% (As of Jun. 2025)


What is Ceryvyn Therapeutics Effective Interest Rate on Debt %?

Ceryvyn Therapeutics CKDXF Effective Interest Rate on Debt % is 30.88% as of Jun. 2025. The stock has 3 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Ceryvyn Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Jun. 2025 was $48.56 Mil. Ceryvyn Therapeutics's average total debt for the quarter that ended in Jun. 2025 was $157.25 Mil. Therefore, Ceryvyn Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2025 was 30.88%.

Ceryvyn Therapeutics  (OTCPK:CKDXF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Ceryvyn Therapeutics Effective Interest Rate on Debt % Related Terms

Ceryvyn Therapeutics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Effective Interest Rate on Debt % Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 15.68 26.61 32.80

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.40 48.85 55.76 29.68 30.88

CKDXF vs VRTX, REGN, ALNY: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Effective Interest Rate on Debt % falls into.


Ceryvyn Therapeutics Effective Interest Rate on Debt % Calculation

Ceryvyn Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Jun. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Jun. 2024 )+Total Debt  (A: Jun. 2025 ))/ count )
=-1  *  -46.457/( (141.647+0)/ 1 )
=-1  *  -46.457/141.647
=32.80 %

where

Total Debt  (A: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=141.554 + 0.093
=141.647

Total Debt  (A: Jun. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

Ceryvyn Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2024 )+Total Debt  (Q: Jun. 2025 ))/ count )
=-1  *  -48.558/( (157.247+0)/ 1 )
=-1  *  -48.558/157.247
=30.88 %

where

Total Debt  (Q: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=157.209 + 0.038
=157.247

Total Debt  (Q: Jun. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Jun. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 30.88% mean?
Ceryvyn Therapeutics (CKDXF) has a Effective Interest Rate on Debt % of 30.88% as of Jun. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Effective Interest Rate on Debt % too high?
Ceryvyn Therapeutics' current Effective Interest Rate on Debt % is 30.88%.
How does Ceryvyn Therapeutics' Effective Interest Rate on Debt % compare to VRTX and REGN?
Ceryvyn Therapeutics' Effective Interest Rate on Debt % of 30.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Effective Interest Rate on Debt % is 30.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (CKDXF) has a current Effective Interest Rate on Debt % of 30.88%. The current Effective Interest Rate on Debt % is 30.88%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Ceryvyn Therapeutics (CKDXF), the current Effective Interest Rate on Debt % is 30.88% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.